Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
Somayya Noori, Charissa Wijnands, Pieter Langerhorst, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 18

Showing 18 citing articles:

Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma
Tadeusz Kubicki, Dominik Dytfeld, David R. Barnidge, et al.
Blood (2024) Vol. 144, Iss. 9, pp. 955-963
Open Access | Times Cited: 9
Measurable Residual Disease and Decision-Making in Multiple Myeloma
Benjamin A. Derman, Rafaël Fonseca
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 2, pp. 477-495
Closed Access | Times Cited: 8
Direct Mass Spectrometry-Based Detection and Antibody Sequencing of Monoclonal Gammopathy of Undetermined Significance from Patient Serum: A Case Study
Weiwei Peng, Maurits A. den Boer, Sem Tamara, et al.
Journal of Proteome Research (2023) Vol. 22, Iss. 9, pp. 3022-3028
Open Access | Times Cited: 17
Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma
Charissa Wijnands, Peter Karel, Jolein Gloerich, et al.
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 135-135
Open Access
Advances in minimal residual disease monitoring in multiple myeloma
Charissa Wijnands, Somayya Noori, Niels W.C.J. van de Donk, et al.
Critical Reviews in Clinical Laboratory Sciences (2023) Vol. 60, Iss. 7, pp. 518-534
Open Access | Times Cited: 11
M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator
Charissa Wijnands, Pieter Langerhorst, Somayya Noori, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2023) Vol. 62, Iss. 3, pp. 540-550
Open Access | Times Cited: 6
M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma
Lihua Guan, Wei Su, Jian Zhong, et al.
Clinica Chimica Acta (2023) Vol. 552, pp. 117623-117623
Closed Access | Times Cited: 5
Proteomics provides insights into the theranostic potential of extracellular vesicles
Morteza Abyadeh, Mehdi Alikhani, Mehdi Mirzaei, et al.
Advances in protein chemistry and structural biology (2023), pp. 101-133
Closed Access | Times Cited: 5
An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients
Charissa Wijnands, Gad Armony, Somayya Noori, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2024) Vol. 62, Iss. 12, pp. 2507-2518
Closed Access | Times Cited: 1
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients
Scott Jew, Sean Bujarski, Bernard Regidor, et al.
Targeted Oncology (2023) Vol. 18, Iss. 5, pp. 735-747
Closed Access | Times Cited: 4
Measurable residual disease in peripheral blood in myeloma: dream or reality
Tadeusz Kubicki, Benjamin A. Derman, Dominik Dytfeld, et al.
Current Opinion in Oncology (2023) Vol. 35, Iss. 6, pp. 574-580
Closed Access | Times Cited: 3
A sensitive high-resolution mass spectrometry method for quantifying intact M-protein light chains in patients with multiple myeloma
Stephané Muccio, Christophe Hirtz, Sandrine Descloux, et al.
Clinica Chimica Acta (2023) Vol. 552, pp. 117634-117634
Closed Access | Times Cited: 3
De novo antibody sequencing based on mass spectrometry
Weiwei Peng
(2024)
Open Access
Improved detection of tryptic immunoglobulin variable region peptides by chromatographic and gas-phase fractionation techniques
Christoph Stingl, Martijn M. VanDuijn, Thomas Dejoie, et al.
Cell Reports Methods (2024) Vol. 4, Iss. 6, pp. 100795-100795
Open Access
Recent Updates in the Diagnosis and Management of Kidney Diseases in Multiple Myeloma
Kenar D. Jhaveri, Priti Meena, Joyita Bharati, et al.
Indian Journal of Nephrology (2024) Vol. 35, pp. 8-20
Open Access
An ATLAS to map MRD with peripheral blood
Andrew J. Yee
Blood (2024) Vol. 144, Iss. 9, pp. 919-920
Closed Access
Lenalidomide maintenance in Myeloma – a goldilocks problem?
Melissa Ng, Amit Khot
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 10, pp. 1611-1614
Closed Access | Times Cited: 1
Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
Ângelo Maiolino, Elaine Sobral da Costa, Alberto Órfão
Frontiers in Oncology (2023) Vol. 13
Open Access
Page 1

Scroll to top